Clinical studies2020-09-08T16:44:12+00:00

Clinical studies

Current and future clinical research involving the Personal Medicine Profile (PMP)

Data from IPSYC study shows the relevance of PGx testing in psychiatry

Aarhus University Hospital Psychiatry, Aarhus, Denmark, shows in a real-world pharmacogenetic frequency study of genotypes and phenotypes among 77.684 persons a high number (72%) of at least one pharmacogenetic variant or divergent phenotype indicating the importance of pharmacogenetic panel-based genotyping. The study also touches upon panel based genotyping could increase the clinical usefulness of PGx testing, as it was shown that 91-96% of the individuals of previously studied cohorts carried at least one actionable gene variant.  Panel-based genotyping can be executed in response to a first drug prescription, and results can be re-used for all subsequent drug prescriptions in the future. https://www.nature.com/articles/s41398-021-01417-4

Personal Medicine Service is successful in Community Pharmacies in the Netherlands

Community pharmacy services have evolved to include medical and pharmaceutical interventions alongside dispensing. The pharmacogenomic testing service was implemented across a selection of community pharmacies in the Netherlands. Data were captured on test outcomes and through a pharmacist survey. Following testing, 17.8% of the clinical samples were recommended to avoid certain medication (based on their current medicines use), and 14.0% to have their dose adjusted. Pre-emptive analysis of genotyped patients showed that the majority (99.2%) had actionable variants. Pharmacists felt confident in their operational knowledge to deliver the service, but less so in applying that knowledge. Delivering the service was believed to improve relationships with other healthcare professionals. These results add to the evidence in understanding how PGx can be delivered effectively within the community pharmacy environment. Training pharmacists in how to respond to patient queries and make clinical recommendations may enhance service provision further. Pharmacy 2021, 9(1), 38; https://doi.org/10.3390/pharmacy9010038

European Society of Cardiology Recommends Genotyping Test prior to treatment

There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials and policy / regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, the newest position statement from February 2021 attempts to address these issues and recommend prospective genotyping test prior to anticoagulants, antipalets, statins and betablockers. European Heart Journal - Cardiovascular Pharmacotherapy, pvab018, https://doi.org/10.1093/ehjcvp/pvab018

Epilepsy: mismatched medication can be fatal

Up to 30% of patients do not respond well to the anticonvulsants they try. A recent report shows that people on a more aggressive treatment regimen, with three or more antiepileptic medications, have a three times lower risk of sudden death than people treated with one AED alone. Combinations including lamotrigine, valproic acid and levetiracetam were associated with reduced risk. Concurrent treatment with statins also reduced the risk of death, while antidepressants had no effect. While no one specific antiepileptic drug was associated with a higher risk than the others, poor adherence to treatment significantly raises the chance of seizure-related death. In general, the chance of side effects increases the more medications a person takes. Pharmacogenetic testing can be instrumental in guiding medication selection and tailoring medication dosage to reduce these risks and improve peace of mind with overall treatment. First published September 23, 2020, DOI: https://doi.org/10.1212/WNL.0000000000010874 Pharmacogenetic testing informs epilepsy treatment Pharmacogenetic tests can assess the metabolism of multiple medications used for epilepsy treatment. Personal Medicine Profile is a leading pharmacogenetic medication optimization service that includes a state-of-the-art pharmacogenetic test and a medication review by a clinical pharmacist. Personal Medicine Profile pharmacists will provide written recommendations for your doctor on safe AED drug selection and dosage ranges to help manage your epilepsy. Summary Epilepsy medication should be matched to epilepsy type and your genetic profile Mismatched treatment can lead to undesired side effects and reduced compliance with treatment, which could be fatal HLA genes determine the risk of SJS, severe AED-induced skin toxicity. Ask your doctor if you are in a high-risk category Pharmacogenetic testing coupled with a pharmacist review of medications can provide insights into your metabolism of many drugs used for epilepsy treatment Knowing your inherited drug metabolic profile can help your doctor select appropriate drug doses and reduce side effects.

Discover The Future

Personal Medicine is how medicine will be prescribed in the future, based on your DNA profile

Contact Us

Go to Top